Thermo Fisher Scientific inaugurated its expanded Research and Development (R&D) Centre of Excellence in Bengaluru, marking a major milestone in its mission to advance antibody design, development, and manufacturing. The inauguration was led by Shri Sanjeev Kumar Gupta, CEO, Karnataka Digital Economy Mission (KDEM). Senior dignitaries from KDEM, KEONICS, and Karnataka Innovation & Technology Society (KITS) were also present.
Strengthening India’s Role in Global Scientific Research
The expansion, backed by an investment exceeding ₹160 crore, underscores Thermo Fisher’s long-term commitment to India’s thriving research ecosystem. The 37,000 sq. ft. facility integrates advanced automation and analytical platforms to support immunoassays, protein analysis, and cell-based studies. Over the next few years, the expansion is expected to nurture local talent. It will also enhance Karnataka’s reputation as a life sciences innovation hub.
Deepening Partnership with Karnataka’s Innovation Ecosystem
Gianluca Pettiti, Executive Vice President and Sector President, Life Sciences, Diagnostics and Applied Sector, Thermo Fisher Scientific, emphasized, “Bengaluru is a strategic hub for Thermo Fisher, and this expansion reflects our long-term commitment to India’s innovation ecosystem. By investing in local talent and capabilities, we aim to accelerate scientific progress and serve our customers more effectively worldwide.”
Two Decades of Scientific Excellence in India
Thermo Fisher’s Bengaluru Centre of Excellence remains a cornerstone of its global R&D network. Over the past 18 years, the facility has developed more than 2,000 recombinant antibodies, contributing to breakthroughs in infectious disease, antiviral research, and cancer biology. The center’s robust antibody validation program has tested over 25,000 antibodies. Its manufacturing capabilities have produced over 2,000 primary and secondary antibodies, ensuring consistent quality and reproducibility for researchers worldwide.
Boosting Karnataka’s Biotechnology and Pharmaceutical Landscape
Dr. Manjula N noted, “This investment complements Karnataka’s vision to harness scientific innovation and build strong industry-academia linkages. Facilities like this catalyze high-end research and reinforce the state’s position as a preferred destination for life sciences and advanced manufacturing.”
As per the press release, Karnataka remains a biotechnology powerhouse. The state contributes over 10% of India’s pharmaceutical revenues and about 60% of biotechnology revenues. The state’s bioeconomy is valued at $31 billion and growing at an annual rate of 10.7%. It houses over 221 formulation units, 74 bulk drug units, and 35 contract research organizations (CROs).
Expanding Bengaluru’s Role in Thermo Fisher’s Global Network
Manoj Prasad, Vice President, IT and Digital Solutions, APAC & MEA, Thermo Fisher Scientific, added, “This expansion reinforces our faith in India’s potential to lead in life sciences innovation. Bengaluru continues to anchor our R&D and product innovation efforts. With new infrastructure and top talent, we can accelerate discovery, strengthen our global network, and support customers in biotech, diagnostics, and academia.”
